MBX Biosciences posts corporate presentation on endocrine, metabolic disease peptide pipeline

MBX Biosciences, Inc.

MBX Biosciences, Inc.

MBX

0.00
  • MBX Biosciences outlined plans to start Phase 3 trial for once-weekly hypoparathyroidism therapy canvuparatide (MBX 2109) in Q3 2026.
  • Phase 2 Avail trial showed 63% responder rate at week 12; open-label extension showed 79% responder rate at 6 months; no treatment-related serious adverse events or discontinuations reported in 12-week trial.
  • Program update flagged Avail Phase 2 presentation with one-year open-label extension data at ENDO 2026.
  • Pipeline milestones include Phase 2a results for imapextide (MBX 1416) in Q2 2026; Phase 1 12-week multiple-ascending-dose results for obesity candidate MBX 4291 (GLP-1/GIP) in Q4 2026.
  • Cash and investments of $440 million as of March 31, 2026, cited as funding runway into 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.